Roth Capital raised the firm’s price target on OptimizeRx (OPRX) to $22 from $16 and keeps a Buy rating on the shares. The company reported strong Q1 results, with revenues and adjusted EBITDA both well above estimates marking a good start in its weakest seasonal quarter, the analyst tells investors in a research note. With net dollar retention of 114% essentially accounting for the firm’s 2025 revenue growth forecast of 14%, the company’s increased 2025 revenue and EBITDA guidance still look conservative, Roth adds.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $12.50 from $8 at Stifel
- OptimizeRx price target raised to $14 from $11 at Citizens JMP
- OptimizeRx Reports Strong Q1 2025 Financial Growth
- OptimizeRx: Strong Financial Performance and Strategic Growth Positioning for Potential Acquisition
- OptimizeRx reports Q1 non-GAAP EPS 8c, consensus (12c)